WestPark Capital analyst issues BUY recommendation for VERU on October 6, 2026 05:38PM ET. VERU was trading at $2.572 at issue of the analyst recommendation.The overall analyst consensus : BUY.Current analyst recommendations are : 6 - Buy, 1 - Hold recommendations .Historical Analyst RecommendationsLatest 10 recommendationsReport DateAnalyst CompanyActionPrevious GradeNew GradePrice when posted 2026-10-06 WestPark Capital...
Richardson Electronics, Ltd. (RELL) confirmed earnings release on October 07, 2026, After the market for the...
Toro Corp. (TORO) confirmed earnings release on October 07, 2026, Before the market for the quarter...
Comtech Telecommunications Corp. (CMTL) confirmed earnings release on October 06, 2026, Before the market for the...
from Capital One Financial issued a price target of $160.00 for BNY on 2026-10-06 12:06:26.The adjusted...
from Capital One Financial issued a price target of $160.00 for BNY on 2026-10-06 12:06:26.The adjusted price target was set to $160.00.At the time of the announcement, BNY was trading...
Jenna Davidner from Barclays issued a price target of $14.00 for XERS on 2026-10-06 09:54:40.The adjusted price target was set to $14.00.At the time of the announcement, XERS was trading...
from Guggenheim issued a price target of $7.00 for OVID on 2026-10-05 20:16:26.The adjusted price target was set to $7.00.At the time of the announcement, OVID was trading at $2.34.The...
Madison El-Saadi from B.Riley Financial issued a price target of $160.00 for SPRB on 2026-10-05 09:07:00.The adjusted price target was set to $160.00.At the time of the announcement, SPRB was...
David Nierengarten from Wedbush issued a price target of $14.00 for STTK on 2026-10-02 11:42:04.The adjusted price target was set to $14.00.At the time of the announcement, STTK was trading...
In a landscape marked by rapid technological advancements, the company saw a revenue increase of $1.4 million for the three months ending September 30, 2024, fueled by new licenses and...
In a landscape of fluctuating revenues, the company celebrated a 25% revenue increase in Q3 2024, yet faced a 14% decline over nine months due to production challenges. Operating expenses...
In a landscape marked by financial challenges, the company faced fluctuating revenues, with a notable 25% increase in Q3 2024 overshadowed by a 14% decline over nine months. Operating losses...
In a tale of growth and ambition, the company witnessed its revenue soar from $6.0 million to $13.9 million, fueled by partnerships with Acadia Pharmaceuticals. However, operating expenses, particularly in...
In a transformative period, the company experienced a remarkable surge in revenue, driven by newly acquired oil and gas assets. Operating expenses showed notable trends, with a decrease in occupancy...
